Skip to main content

Table 4 Multivariate Cox proportional hazards ratios for association between HER2 measurements by HERmark, selected clinicopathological variables and overall survival

From: Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

 

Overall survival

 

HR

P value

Model A

  

  HERmark positive vs. negative*

3.1

0.034

  Grade 3 vs. 1 or 2

2.0

0.26

  Stage III or IV vs. I or II

0.93

0.89

  Node positive vs. negative

1.7

0.38

  Hormone receptor positive vs. negative

0.43

0.071

Model B

  

  H2T high vs. low#

3.9

0.0061

  Grade 3 vs. 1 or 2

1.7

0.30

  Stage III or IV vs. I or II

0.91

0.84

  Node positive vs. negative

1.9

0.26

  Hormone receptor positive vs. negative

0.54

0.15

  1. *HERmark status based on HERmark analytical cutoffs in Model A: HERmark positive - H2T >17.8 relative fluorescence (RF)/mm2; HERmark negative - H2T <10.5 RF/mm2. #HER2 levels based on HERmark clinical cutoff in Model B: H2T high - H2T >13.8 RF/mm2; H2T low- H2T ≤13.8 RF/mm2. HER2, human epidermal growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark; HR, hazard ratio.